
    
      This is a Phase 2, open-label, multi-center, 2x2 crossover study assessing the safety and
      efficacy of MS1819-SD vs porcine PERT given at the same dose that was being administered
      during the pre-study period.

      MS1819-SD will be assessed in a 2x2 crossover including at least 30 patients completing both
      periods.
    
  